{"title":"使用布加替尼治疗进展中的alk阳性NSCLC","authors":"S.Y. Krutelev, К. Laktionov","doi":"10.31917/2402194","DOIUrl":null,"url":null,"abstract":"non-small cell lung cancer, ALK translocation, brigatinib, resistance","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"85 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The use of brigatinib in the treatment of ALK-positive NSCLC in the progression of crizotinib\",\"authors\":\"S.Y. Krutelev, К. Laktionov\",\"doi\":\"10.31917/2402194\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"non-small cell lung cancer, ALK translocation, brigatinib, resistance\",\"PeriodicalId\":101072,\"journal\":{\"name\":\"Reports of Practical Oncology\",\"volume\":\"85 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reports of Practical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31917/2402194\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31917/2402194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
